Patent intelligence · US
US 8338632
Cycloalkylmethylamines
Cycloalkylmethylamines
Patent details — US 8338632
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 25, 2012
- Expiration
- Dec 20, 2032
- Applicant
- REVIVA PHARMACEUTICALS, INC.
- Claims
- 18
- CPC classes
- A61P, A61P1/00, A61P1/04, A61P1/08
Quick answer
US 8338632 (Cycloalkylmethylamines) is held by REVIVA PHARMACEUTICALS, INC.. Status: granted. Granted Dec 25, 2012. Expires Dec 20, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REVIVA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61P, A61P1/00, A61P1/04, A61P1/08, A61P13/00, A61P15/00
More from REVIVA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12053477
Methods for treating pulmonary fibrosis
granted -
US 10441590
Methods for treating pulmonary hypertension
granted -
US 10035761
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
granted -
US 9975862
Arylpiperazine derivatives and methods of utilizing same
granted -
US 9907803
Methods for treating attention deficit hyperactivity disorder
granted -
US 9695116
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
granted -
US 9604944
Arylpiperazine derivatives and methods of utilizing same
granted -
US 9302981
Synthesis, methods of using, and compositions of cycloalkylmethylamines
granted
Frequently asked questions
What is US patent 8338632?
US 8338632 (Cycloalkylmethylamines) is held by REVIVA PHARMACEUTICALS, INC.. Status: granted. Granted Dec 25, 2012. Expires Dec 20, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8338632?
REVIVA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 8338632 expire?
Our index shows an expiration date of Dec 20, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.